FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3149808834> ?p ?o ?g. }

• W3149808834 abstract "Background: The coronavirus disease (COVID-19), caused by the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), prompted a global health crisis, with no available specific treatments. Convalescent plasma (CP) with neutralizing antibodies could be a promising therapeutic approach to reduce mortality. Objectives: To evaluate the therapeutic potential of CP for COVID-19 and to assess its safety and efficacy in reducing the patients' mortality. Methods: We retrieved clinical trial references from multiple Databases (e.g., PubMed, B-On, SCOPUS), for complete studies until November 26th 2020. We included Randomized controlled trials (RCT) and controlled non-randomized trials (CNRT), that assessed the efficacy of CP to treat hospitalized COVID-19 patients. Trials were included regardless of concomitant medications in the intervention's arms. Eleven trials met our eligibility criteria. This study was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines. We defined a methodological protocol to extract and evaluate all pertinent baseline demographics and interventions' characteristics from trials. The primary outcomes were the safety profile of CP, measured by the type, frequency and severity of adverse events, and CP effectiveness in reducing mortality, measured by the number of deaths registered for this therapy. Results: We assessed 11 trials (5 RCT and 6 CNRT) with 3,098 participants, of whom 923 patients were treated with CP. Only 32 (3.5%) of the treated patients suffered adverse events (from which 9.4% serious transfusion-related adverse events). The overall mortality rates were significantly decreased by CP administration {risk ratio (RR) 0.71, p = 0.005, 95% confidence interval (Cl) [0.57–0.90]}, with low heterogeneity. In the sub-analysis by period of transfusion, CP transfusion within a week of hospitalization contributed to diminished mortality rate (RR = 0.71, p = 0.03, 95%Cl [0.53–0.96]). CP therapy also led to significantly reduced viral loads at 72 h after transfusion (RR = 0.61, p = 0.04, 95%Cl [0.38–0.98]), despite high heterogeneity due to disease severity. Conclusion: This meta-analysis established CP as a safe and potentially effective therapy for COVID-19, decreasing the mortality rates and promoting a swift viral clearance. Further studies are necessary to provide stronger evidence." @default.
• W3149808834 created "2021-04-13" @default.
• W3149808834 creator A5000027398 @default.
• W3149808834 creator A5005096269 @default.
• W3149808834 creator A5037437882 @default.
• W3149808834 creator A5083558974 @default.
• W3149808834 creator A5090457672 @default.
• W3149808834 creator A5091123256 @default.
• W3149808834 date "2021-04-06" @default.
• W3149808834 modified "2023-10-12" @default.
• W3149808834 title "Assessment of the Safety and Therapeutic Benefits of Convalescent Plasma in COVID-19 Treatment: A Systematic Review and Meta-Analysis" @default.
• W3149808834 cites W1496308634 @default.
• W3149808834 cites W2096238447 @default.
• W3149808834 cites W2148822770 @default.
• W3149808834 cites W2412511529 @default.
• W3149808834 cites W2549455555 @default.
• W3149808834 cites W3008827533 @default.
• W3149808834 cites W3009582878 @default.
• W3149808834 cites W3009932851 @default.
• W3149808834 cites W3011379523 @default.
• W3149808834 cites W3013348202 @default.
• W3149808834 cites W3014735311 @default.
• W3149808834 cites W3014853902 @default.
• W3149808834 cites W3015807479 @default.
• W3149808834 cites W3019834697 @default.
• W3149808834 cites W3021816206 @default.
• W3149808834 cites W3022872787 @default.
• W3149808834 cites W3025192328 @default.
• W3149808834 cites W3025626988 @default.
• W3149808834 cites W3032394272 @default.
• W3149808834 cites W3035940803 @default.
• W3149808834 cites W3036493157 @default.
• W3149808834 cites W3038242174 @default.
• W3149808834 cites W3040406962 @default.
• W3149808834 cites W3041639190 @default.
• W3149808834 cites W3042487110 @default.
• W3149808834 cites W3047044993 @default.
• W3149808834 cites W3082225243 @default.
• W3149808834 cites W3085955680 @default.
• W3149808834 cites W3093711492 @default.
• W3149808834 cites W3097625809 @default.
• W3149808834 cites W3110542218 @default.
• W3149808834 cites W4244545939 @default.
• W3149808834 doi "https://doi.org/10.3389/fmed.2021.660688" @default.
• W3149808834 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8055850" @default.
• W3149808834 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33889590" @default.
• W3149808834 hasPublicationYear "2021" @default.
• W3149808834 type Work @default.
• W3149808834 sameAs 3149808834 @default.
• W3149808834 citedByCount "10" @default.
• W3149808834 countsByYear W31498088342021 @default.
• W3149808834 countsByYear W31498088342022 @default.
• W3149808834 crossrefType "journal-article" @default.
• W3149808834 hasAuthorship W3149808834A5000027398 @default.
• W3149808834 hasAuthorship W3149808834A5005096269 @default.
• W3149808834 hasAuthorship W3149808834A5037437882 @default.
• W3149808834 hasAuthorship W3149808834A5083558974 @default.
• W3149808834 hasAuthorship W3149808834A5090457672 @default.
• W3149808834 hasAuthorship W3149808834A5091123256 @default.
• W3149808834 hasBestOaLocation W31498088341 @default.
• W3149808834 hasConcept C126322002 @default.
• W3149808834 hasConcept C168563851 @default.
• W3149808834 hasConcept C177713679 @default.
• W3149808834 hasConcept C197934379 @default.
• W3149808834 hasConcept C44249647 @default.
• W3149808834 hasConcept C535046627 @default.
• W3149808834 hasConcept C71924100 @default.
• W3149808834 hasConcept C82789193 @default.
• W3149808834 hasConcept C95190672 @default.
• W3149808834 hasConceptScore W3149808834C126322002 @default.
• W3149808834 hasConceptScore W3149808834C168563851 @default.
• W3149808834 hasConceptScore W3149808834C177713679 @default.
• W3149808834 hasConceptScore W3149808834C197934379 @default.
• W3149808834 hasConceptScore W3149808834C44249647 @default.
• W3149808834 hasConceptScore W3149808834C535046627 @default.
• W3149808834 hasConceptScore W3149808834C71924100 @default.
• W3149808834 hasConceptScore W3149808834C82789193 @default.
• W3149808834 hasConceptScore W3149808834C95190672 @default.
• W3149808834 hasLocation W31498088341 @default.
• W3149808834 hasLocation W31498088342 @default.
• W3149808834 hasLocation W31498088343 @default.
• W3149808834 hasOpenAccess W3149808834 @default.
• W3149808834 hasPrimaryLocation W31498088341 @default.
• W3149808834 hasRelatedWork W1539974851 @default.
• W3149808834 hasRelatedWork W2112436308 @default.
• W3149808834 hasRelatedWork W2355769538 @default.
• W3149808834 hasRelatedWork W2362391294 @default.
• W3149808834 hasRelatedWork W2373885168 @default.
• W3149808834 hasRelatedWork W2611523470 @default.
• W3149808834 hasRelatedWork W2956460282 @default.
• W3149808834 hasRelatedWork W2976934717 @default.
• W3149808834 hasRelatedWork W3139914494 @default.
• W3149808834 hasRelatedWork W3210678099 @default.
• W3149808834 hasVolume "8" @default.
• W3149808834 isParatext "false" @default.
• W3149808834 isRetracted "false" @default.
• W3149808834 magId "3149808834" @default.
• W3149808834 workType "article" @default.